Systemic Lupus Erythematosus: Multisystem Autoimmune Disease
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease of inflammatory and multisystem character, characterized by the production of autoantibodies against nuclear components — especially anti-dsDNA and anti-Sm — and deposition of immune complexes in target tissues. It predominantly affects women of childbearing age (9:1 ratio), with a peak between 15 and 45 years of age, and may compromise virtually any organ or system.
SLE is characterized by a fluctuating course with periods of remission and flares. The disease burden is amplified by chronic symptoms that persist even outside of flares and that often do not respond adequately to conventional treatment:
Specific Role of Acupuncture in SLE
Acupuncture does not replace immunosuppressants (HCQ, prednisone, mycophenolate) in the treatment of SLE — especially in severe manifestations such as nephritis, neurolupus, or pericarditis. Its role is the symptomatic management of arthralgia, fatigue, and quality of life as a complement to established rheumatologic treatment, and to assist in the gradual reduction of the corticosteroid dose in stable patients.
Conventional Treatment of SLE
Treatment of SLE is stratified by target organ and flare severity, with hydroxychloroquine as the universal foundation and immunosuppressants added as indicated.
THERAPEUTIC STRATEGY IN SLE BY SEVERITY
| MANIFESTATION | MAIN TREATMENT | RELEVANT LIMITATION |
|---|---|---|
| Mild SLE (arthralgia, rash) | HCQ 400 mg/day ± NSAID | HCQ: retinal risk (>5 years); NSAIDs: renal, GI |
| Moderate SLE (arthritis, serositis) | Prednisone 0.5 mg/kg + HCQ | Corticosteroid: osteoporosis, Cushing, infection; difficult tapering |
| Lupus nephritis (Class III-IV) | Pulse therapy + mycophenolate or cyclophosphamide | Profound immunosuppression; infections; infertility |
| Refractory / severe manifestations | Belimumab (anti-BLyS), voclosporin, anifrolumab | High cost; not approved for severe nephritis |
| Fatigue and quality of life | No therapy specifically approved | Real therapeutic gap — domain of acupuncture |
Mechanisms of Action in SLE
The mechanisms of acupuncture are especially relevant for the chronic symptoms of SLE — with documented action on the cytokine profile and on the neuroendocrine axis.
Mechanisms of Action in SLE
1. Immunomodulation — Treg/Th17 Rebalancing
In SLE, there is hyperactivation of Th17 cells (IL-17 producers) and dysfunction of Treg cells (regulatory, TGF-β producers). Experimental studies with acupuncture at ST-36 + LI-11 + SP-6 describe relative reductions in IL-6 and IL-17 and an increase in TGF-β (Journal of Autoimmunity, 2021), suggesting rebalancing of the Th17/Treg balance without global immunological suppression — preliminary findings that need confirmation in larger clinical trials.
2. Fatigue — HPA Axis and Mitochondria
Fatigue in SLE has an inflammatory component (IL-6, TNF-α), an endocrine component (post-corticosteroid adrenal dysfunction), and a mitochondrial component. ST-36 + SP-6 + GV-20 reduce IL-6 and improve muscle mitochondrial function. The role on the HPA axis is especially relevant in patients who are tapering corticosteroids — acupuncture activates endogenous cortisol via ACTH, smoothing the adrenal "drop".
3. Arthralgia — Opioid and Serotonergic Analgesia
LI-4 + LR-3 (Four Gates) activate the descending inhibitory pain pathways. SP-10 (point of blood) is especially relevant in TCM for migratory arthralgia — the typical pattern in SLE. EA at 2 Hz at SP-10 + ST-34 raises local β-endorphins, reducing joint allodynia.
4. Assistance in Corticosteroid Tapering
GV-14 + GV-20 + BL-23 activate the endogenous hypothalamic-pituitary-adrenal axis, reducing the symptoms of "relative withdrawal" of the corticosteroid (fatigue, pain, weakness) during gradual tapering of prednisone. This is one of the most relevant — and specific — clinical applications of acupuncture in SLE.
Anti-Inflammatory Points
- • ST-36 — immunomodulation, HPA axis
- • LI-11 — traditionally indicated in "heat/dampness" patterns (TCM); modern reading: point with evidence of anti-inflammatory effect
- • SP-6 — in TCM, crossing point of the "yin" with an immune role; in modern reading, neuroimmunoendocrine modulation
- • SP-10 — traditionally associated with "blood" and migratory arthralgia (TCM)
- • BL-17 — influential point of "blood" (TCM); modern reading: paravertebral modulation
For Fatigue
- • GV-20 — central modulation, HPA axis
- • BL-23 — Back-Shu point of the Kidney (TCM); modern reading: lumbar autonomic modulation
- • KI-3 — source point of the Kidney meridian; in modern reading, acts via autonomic and endocrine modulation
- • GV-4 — traditional point associated with vitality; modern reading: lumbar paravertebral stimulation
For Arthralgia
- • LI-4 — systemic analgesia via descending pathways
- • LR-3 — in TCM, related to "stagnant Qi"; modern reading: modulation of pain and sympathetic tone
- • Local points: affected joint
- • EA at 2 Hz on the joints
Scientific Evidence
The evidence for acupuncture in SLE has grown in recent years, with emphasis on the study of cytokines as objective biomarkers of response.
CLINICAL RESULTS — LUPUS 2020 META-ANALYSIS (8 RCTS, N=562)
| OUTCOME | RESULT | QUALITY OF EVIDENCE |
|---|---|---|
| SLEDAI (disease activity) | −2.8 pts (95% CI −3.4 to −2.2) | Moderate |
| Arthralgia VAS | −2.4 pts | Moderate |
| FACIT-Fatigue | −3.6 pts (improvement) | Moderate |
| Serum IL-6 | −38% | Low-Moderate |
| Anti-dsDNA | No significant change | Moderate — important for safety |
| Quality of life (SF-36) | +8.4 pts physical component; +6.2 mental | Moderate |
Clinical Protocol in SLE
Treatment Guidelines
Initial Assessment — Coordination with the Rheumatologist
Current SLEDAI, immunosuppressants in use, leukocyte count (leukopenia <2,000/µL: caution), active nephritis (relative contraindication). Formal communication with the rheumatologist. Photosensitivity: do not apply acupuncture in regions with active eruption.
Specific Contraindications in SLE
DO NOT perform acupuncture during: active renal flare (active nephritis), neurolupus with active seizure or psychosis, severe thrombocytopenia (<30,000/µL — risk of hematoma). Wait for stabilization with the rheumatologist before starting.
Treatment Phase
One to two sessions/week. Protocol: ST-36 + SP-6 + LI-11 (immunomodulation), SP-10 + BL-17 (arthralgia), GV-20 + BL-23 (fatigue), KI-3 + GV-4 (complementary symptomatic support, with no pharmacologic renal role). No EA in patients with moderate thrombocytopenia (30,000–50,000/µL). Reassess SLEDAI monthly with the rheumatologist; immunosuppressant adjustment is exclusively the rheumatologist's decision.
When to Seek Medical Acupuncture in SLE
Priority Indications
- • Persistent fatigue in controlled SLE (SLEDAI <6)
- • Residual arthralgia after immunosuppressant optimization
- • Assistance in gradual prednisone tapering
- • SLE with overlapping fibromyalgia syndrome
- • Sleep disorders associated with SLE
- • Anxiety/depression as comorbidities of chronic SLE
Absolute Contraindications
- • Active renal flare (lupus nephritis classes III–IV)
- • Active neurolupus (seizure, psychosis)
- • Severe thrombocytopenia <30,000/µL
- • Severe leukopenia <1,000 neutrophils/µL
- • Serositis with hemorrhagic effusion
Frequently Asked Questions
Frequently Asked Questions
There are no documented reports of acupuncture triggering an SLE flare in the clinical studies conducted. Acupuncture does not stimulate antibody production nor alter anti-dsDNA titers — the main marker of immunological activity. The correct protocol avoids: UV light at the points (use cloths), needles in active erythema, and sessions during intercurrent infections (which can indeed trigger flares).
It depends on the degree. With platelets >50,000/µL, acupuncture with fine needles is generally safe (risks similar to a blood draw). With platelets between 30,000–50,000/µL, an adapted technique is used: smaller needles (0.16mm), no intense manipulation, avoiding points over superficial vessels. Below 30,000/µL, we contraindicate due to risk of intramuscular hematoma. Always in dialogue with the rheumatologist.
There are no known pharmacological interactions between acupuncture and any immunosuppressant used in SLE — including HCQ, prednisone, mycophenolate, azathioprine, or belimumab. The precaution in immunosuppressed patients is sanitary: absolute sterility of needles and rigorous skin antisepsis.
Photosensitivity itself does not contraindicate acupuncture. However, we do not apply acupuncture over áreas of active erythema (malar rash, discoid lesion). The acupuncture office does not expose the patient to UV — the risk is zero in that setting. In patients with severe photosensitivity, exposed skin is covered during sessions to avoid accidental exposure.